ADRB2 and lymphoma: These results confirm that blocking the STAT3-pathway, ATP and itaconate metabolism, by (1) blockade of β2-AR signaling, or (2) blocking ETC and ATP generation, or (3) blocking itaconate generation result in disrupted MDSC mitochondrial fitness determining the response to the doxorubicin chemotherapy anti-lymphoma effect and survival.